These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22155821)

  • 1. Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.
    Louie A; VanScoy BD; Brown DL; Kulawy RW; Heine HS; Drusano GL
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1229-39. PubMed ID: 22155821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system.
    Louie A; Vanscoy BD; Heine HS; Liu W; Abshire T; Holman K; Kulawy R; Brown DL; Drusano GL
    Antimicrob Agents Chemother; 2012 Jan; 56(1):513-7. PubMed ID: 22064542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Combination Drug Therapy for Treatment of Antibiotic-Resistant Inhalation Anthrax in a Murine Model.
    Heine HS; Shadomy SV; Boyer AE; Chuvala L; Riggins R; Kesterson A; Myrick J; Craig J; Candela MG; Barr JR; Hendricks K; Bower WA; Walke H; Drusano GL
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696235
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
    Drusano GL; Okusanya OO; Okusanya AO; van Scoy B; Brown DL; Fregeau C; Kulawy R; Kinzig M; Sörgel F; Heine HS; Louie A
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4718-25. PubMed ID: 19687233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro evaluation of the effect of linezolid and levofloxacin on Bacillus anthracis toxin production, spore formation and cell growth.
    Head BM; Alfa M; Sitar DS; Rubinstein E; Meyers AF
    J Antimicrob Chemother; 2017 Feb; 72(2):417-420. PubMed ID: 27798209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tetrazole-Based
    Alumasa JN; Goralski TDP; Keiler KC
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760903
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.
    Louie A; Heine HS; Kim K; Brown DL; VanScoy B; Liu W; Kinzig-Schippers M; Sörgel F; Drusano GL
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2486-96. PubMed ID: 18458134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clindamycin and quinolone therapy for Bacillus anthracis Sterne infection in 60Co-gamma-photon-irradiated and sham-irradiated mice.
    Brook I; Germana A; Giraldo DE; Camp-Hyde TD; Bolduc DL; Foriska MA; Elliott TB; Thakar JH; Shoemaker MO; Jackson WE; Ledney GD
    J Antimicrob Chemother; 2005 Dec; 56(6):1074-80. PubMed ID: 16239289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits.
    Weiss S; Altboum Z; Glinert I; Schlomovitz J; Sittner A; Bar-David E; Kobiler D; Levy H
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7497-503. PubMed ID: 26392505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic susceptibility of isolates of Bacillus anthracis, a bacterial pathogen with the potential to be used in biowarfare.
    Jones ME; Goguen J; Critchley IA; Draghi DC; Karlowsky JA; Sahm DF; Porschen R; Patra G; DelVecchio VG
    Clin Microbiol Infect; 2003 Sep; 9(9):984-6. PubMed ID: 14616693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis?
    Drusano GL; Okusanya OO; Okusanya A; Van Scoy B; Brown DL; Kulawy R; Sörgel F; Heine HS; Louie A
    Antimicrob Agents Chemother; 2008 Nov; 52(11):3973-9. PubMed ID: 18725437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
    Presterl E; Mueller-Uri P; Grisold A; Georgopoulos A; Graninger W
    Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):486-9. PubMed ID: 11561805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations.
    Carryn S; Van Bambeke F; Mingeot-Leclercq MP; Tulkens PM
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2095-103. PubMed ID: 12069960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis].
    Soriano A; Jurado A; Marco F; Almela M; Ortega M; Mensa J
    Rev Esp Quimioter; 2005 Jun; 18(2):168-72. PubMed ID: 16130039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial effects of interferon-inducible CXC chemokines against Bacillus anthracis spores and bacilli.
    Crawford MA; Zhu Y; Green CS; Burdick MD; Sanz P; Alem F; O'Brien AD; Mehrad B; Strieter RM; Hughes MA
    Infect Immun; 2009 Apr; 77(4):1664-78. PubMed ID: 19179419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolates.
    Molitoris D; Väisänen ML; Bolaños M; Finegold SM
    Antimicrob Agents Chemother; 2006 May; 50(5):1887-9. PubMed ID: 16641470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative pre-approved and novel therapies for the treatment of anthrax.
    Head BM; Rubinstein E; Meyers AF
    BMC Infect Dis; 2016 Nov; 16(1):621. PubMed ID: 27809794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.
    Ba BB; Feghali H; Arpin C; Saux MC; Quentin C
    Antimicrob Agents Chemother; 2004 Mar; 48(3):946-53. PubMed ID: 14982788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bacteriolytic agent that detects and kills Bacillus anthracis.
    Schuch R; Nelson D; Fischetti VA
    Nature; 2002 Aug; 418(6900):884-9. PubMed ID: 12192412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bactericidal activity of levofloxacin, gatifloxacin, penicillin, meropenem and rokitamycin against Bacillus anthracis clinical isolates.
    Drago L; De Vecchi E; Lombardi A; Nicola L; Valli M; Gismondo MR
    J Antimicrob Chemother; 2002 Dec; 50(6):1059-63. PubMed ID: 12461034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.